Chronic cerebral hypoperfusion induced degeneration of nerve cells is one of the important factors in low social ability in patients with cognitive dysfunction,and is closely linked to pathology of neurodegenerative and cerebrovascular disease.Domestic and foreign researches on Endocannabinoid toxin (ECS) including G protein-coupled receptor CB1,CB2,AEA,2-AG endogenous ligand and its endogenous ligand deactivation system AEA hydrolase FAAH have shown that ECS has a neuroprotective effect of endogenous physiological regulation mediated in mammalian central nervous system,which is mainly manifested in the receptor level,deactivation system,immune responses and synaptic plasticity and so on.This article is to review the endocannabinoid system (ECS) effects on cognitive impairment in patients with chronic cerebral hypoperfusion.
WU Yi-fang
,
YU Fei
,
SU Shao-hua
,
HAI Jian
. The regulatory effects of the endocannabinoid system on cognitive dysfunction in patient with chronic cerebral hypoperfusion[J]. Surgical Research and New Technique, 2013
, 2(1)
: 41
-44
.
DOI: 10.3969/j.issn.2095-378X.2013.01.010
[1] Demuth DG,Mollema A.Cannabinoid signaling [J].Life Sci,2006,78(6):549-563.
[2] Bosier B,Muccioli GG,Hermans E,et al.Functionally selective cannabinoid receper signaling:therapeutic implications and opportunities[J].Biochem Pharmacol,2010,80(1):1-12.
[3] Tagliaferro P,Javier Ramos A,Onaivi ES,et al.Neuronal cytoskeleton and synaptic densities are altered after a chronic treatment with the cannabinoid receptor agonist WIN 55,212-2[J].Brain Res,2006,1085(1):163-176.
[4] Hill MN,Patel S Campolongo P,et al.Functional interactions Between stress and the endocannabinoid system:from synaptic signaling to behavioral output[J].J Neurosci,2010,30(45):14980-14986.
[5] Mechoulam R,Ben-Shabat S,Hanu L,et al.Identification of an endogenous 2-monoglyceride,present in canine gut,that binds to cannabinoid receptors.Biochem Pharmacol[J],1995,50(1):83-90.
[6] Hanu L,Abu-Lafi S,Fride E,et al.2-arachidonyl glyceryl ether,an endogenous agonist of the cannabinoid CB1 receptor[J].Proc Natl Acad Sci,2001,98(7):3662-3665.
[7] Micale V,Mazzola C,Drago F,et al.Endocannabinoids and neurodegenerative diseases[J].Pharmaco Res.2007,56(5):382-392.
[8] Tagliaferro P,Javier Ramos A Onaivi ES,et al.Neuronal cytoskeleton and synaptic densities are altered after a chronic treatment with the cannabinoid receptor agonist WIN 55,212-2[J].Brain Res,2006,1085(1):163-176.
[9] Cachope R,Mackie K,Triller A,et al.Potentiation of electrical and chemical synaptictransmission mediated by endocannabinoids[J].Neuron,2007,56(6):1034-1047.
[10] Hayakawa K,MishimK,Abe K,et a1.Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism[J].Neuroreport,2004,15(15):2381-2385.
[11] Mauler F,Miaendorf J,De Vry J,et al.Characterization of the diarylether sulfonylester(-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-l-sulf nate(BAY 38-7271) as a potent cannabinoid receptor agonia with neuroprotective properties[J].J Pharmacol Exp Ther,2002,302(1):359-368.
[12] Nagayama T,Sinor AD,Simon RP,et a1.Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures[J].J Neurosci,1999,19(8):2987-2995.
[13] Pellegrini-Giampietro DE,Mannaioni G.Post-ischemic brain damage:the endocannabinoid system in the mechanisms of neuronal death[J].FEBS J,2009,276(1):2-12.
[14] Wagner JA,Jarai Z,Batkai S et al.Hemodynamic effects of cannabinoids:coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors[J].Eur J Pharmacol.2001,423(2-3):203-2l0.
[15] Ferraro L,Tomasini MC,Gessa GL,et a1.The Cannabinoid Receptor Agonist WIN55,212-2 Regulates Glutamate Transmission in Rat Cerebral Cortex:all In Vivo and In Vitro Study[J].Cerebral Cortex,2001,ll(8):728-733.
[16] Domenici MR,Azad SC,Marsicano G,et a1.Cannabinoid receptor type l Located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic Transmission[J].J Neurosci.2006,26(21):5794-5799.
[17] Hillard CJ.Endocannabinoids and vascular function[J].J Pharmacol Exp Ther,2000,294(1):27-32.
